Journal article

A Randomized, Double-Blinded, Placebo-Controlled Phase II Trial of Recombinant Human Leukemia Inhibitory Factor (rhuLIF, Emfilermin, AM424) to Prevent Chemotherapy-Induced Peripheral Neuropathy

ID Davis

Clinical Cancer Research | American Association for Cancer Research (AACR) | Published : 2005

University of Melbourne Researchers